Lebrikizumab

Eli Lilly CEO David Ricks earned $29.2 million in 2024, surpassing Johnson & Johnson's Joaquin Duato to become the highest-paid pharmaceutical executive with a 10% increase from 2023.

Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.

Phase 3 trial data demonstrates lebrikizumab's efficacy in managing atopic dermatitis (AD) symptoms over 52 weeks, a significant improvement over the 16-week maintenance shown in previous trials.

Extended lebrikizumab treatment demonstrates significant efficacy in atopic dermatitis patients who initially did not meet primary response criteria at 16 weeks. By week 52, over 75% of these patients achieved EASI 75, with substantial improvements in itch severity and investigator global assessment scores.

• Eli Lilly's EBGLYSS demonstrated significant improvements in skin condition and itch relief in moderate-to-severe atopic dermatitis patients who had an inadequate response to dupilumab. • In the Phase IIIb ADapt study, 57% of patients achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) score by week 16, increasing to 60% by week 24. • More than half of the patients experienced significant itch relief, with 53% at week 16 and 62% at week 24 showing at least a four-point improvement from baseline. • Clear or almost clear facial dermatitis was observed in 52% of patients treated with EBGLYSS by week 24, with a safety profile consistent with prior Phase III trials.